Amneal Pharmaceuticals (AMRX) Announces FDA Approval of Prednisolone Acetate Ophthalmic Suspension

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) is one of the 13 Best Healthcare Stocks to Buy Under $10. On June 12, Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) announced the FDA approval of prednisolone acetate ophthalmic suspension, with launch planned for Q3 2025.

Is Amneal Pharmaceuticals, Inc. (AMRX) the Best Pharma Stock to Buy for Long Term Growth?

A pharmaceutical laboratory filled with shelves of medicines, highlighting the company’s specialty drug production.

Prednisolone acetate ophthalmic suspension, USP 1% is a topical, sterile anti-inflammatory agent for ophthalmic use and treatment of steroid-responsive ocular inflammation.

Andy Boyer, Executive Vice President and Chief Commercial Officer, Affordable Medicines, stated that the Affordable Medicines portfolio is growing continuously, with a diverse and strong pipeline supporting “broader access to high-quality treatments across the US healthcare system.”

Boyer also stated that the prednisolone acetate ophthalmic suspension is a complex product to manufacture and develop, and its approval reflects the quality of Amneal Pharmaceuticals, Inc.’s R&D capabilities and the strength of its supply and manufacturing operations.

Amneal Pharmaceuticals, Inc. is a medicine company that develops pharmaceuticals, with a product portfolio spanning specialty, generics, biosciences, and product catalog. Its operations are divided into the Generics, Specialty, and AvKARE segments.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

This article is originally published at Insider Monkey.